atenolol has been researched along with Stroke in 89 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 9.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The aim of this study was to analyze the cost-effectiveness of losartan compared with atenolol in the treatment of stroke from the Dutch health care perspective." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 9.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "A total of 4327 men and women, aged > or = 60 years, with isolated systolic hypertension, randomized to placebo or chlorthalidone, with the addition of atenolol or reserpine if needed, were observed for 5 years." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "Among the elderly, atenolol was associated with an increased risk of stroke (relative risk [RR], 1." | 8.90 | Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. ( Khan, NA; Kuyper, LM, 2014) |
| "Relevant randomized clinical trials and review articles were identified through a MEDLINE search of English-language articles published between 1990 and 2006 using the search terms losartan, atenolol, LIFE, hypertension, and LVH." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 8.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "Routine use of preoperative metoprolol, but not atenolol, is associated with stroke after noncardiac surgery, even after adjusting for comorbidities." | 7.79 | Perioperative metoprolol and risk of stroke after noncardiac surgery. ( Freundlich, RE; Kheterpal, S; Mashour, GA; Matlen, L; Merte, J; Nallamothu, BK; Shanks, A; Sharifpour, M; Tremper, KK; Vlisides, PE; Weightman, A, 2013) |
| "The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol." | 7.79 | Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 7.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "To test the effects of atenolol and amlodipine, either alone or in combination, on blood pressure, blood pressure variability (BPV), baroreflex sensitivity (BRS), and the prevalence of stroke in stroke-prone spontaneously hypertensive rats (SHR-SP)." | 7.74 | Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. ( Cai, GJ; Ling, G; Liu, AJ; Liu, JG; Shen, FM; Su, DF, 2007) |
| "From a Canadian societal perspective, losartan appears to be a cost-effective alternative to atenolol in patients with hypertension and LVH." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 7.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hypertension and other vascular risk factors and the Medical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years." | 5.14 | Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. ( Dahlöf, B; Dobson, JE; Dolan, E; Howard, SC; O'Brien, E; Poulter, NR; Rothwell, PM; Sever, PS, 2010) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 5.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The aim of this study was to analyze the cost-effectiveness of losartan compared with atenolol in the treatment of stroke from the Dutch health care perspective." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 5.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "A total of 4327 men and women, aged > or = 60 years, with isolated systolic hypertension, randomized to placebo or chlorthalidone, with the addition of atenolol or reserpine if needed, were observed for 5 years." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "Among the elderly, atenolol was associated with an increased risk of stroke (relative risk [RR], 1." | 4.90 | Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. ( Khan, NA; Kuyper, LM, 2014) |
| "To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke." | 4.88 | A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. ( Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO, 2012) |
| "Relevant randomized clinical trials and review articles were identified through a MEDLINE search of English-language articles published between 1990 and 2006 using the search terms losartan, atenolol, LIFE, hypertension, and LVH." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 4.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "An amlodipine-based BP regimen reduced the long-term incidence of stroke compared with an atenolol-based regimen but had no measurable effect on dementia." | 4.02 | Long-Term Incidence of Stroke and Dementia in ASCOT. ( Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN, 2021) |
| "Risk of incident stroke was examined in relation to abnormal PTFV1 on a baseline ECG in 7778 hypertensive patients with ECG left ventricular hypertrophy, no history of atrial fibrillation, in sinus rhythm on their baseline ECG with no incident atrial fibrillation during follow-up, who were randomly assigned to losartan-based or atenolol-based treatment." | 3.83 | Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. ( Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM, 2016) |
| "The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol." | 3.79 | Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013) |
| "Routine use of preoperative metoprolol, but not atenolol, is associated with stroke after noncardiac surgery, even after adjusting for comorbidities." | 3.79 | Perioperative metoprolol and risk of stroke after noncardiac surgery. ( Freundlich, RE; Kheterpal, S; Mashour, GA; Matlen, L; Merte, J; Nallamothu, BK; Shanks, A; Sharifpour, M; Tremper, KK; Vlisides, PE; Weightman, A, 2013) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 3.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "To test the effects of atenolol and amlodipine, either alone or in combination, on blood pressure, blood pressure variability (BPV), baroreflex sensitivity (BRS), and the prevalence of stroke in stroke-prone spontaneously hypertensive rats (SHR-SP)." | 3.74 | Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. ( Cai, GJ; Ling, G; Liu, AJ; Liu, JG; Shen, FM; Su, DF, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 3.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "From a Canadian societal perspective, losartan appears to be a cost-effective alternative to atenolol in patients with hypertension and LVH." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| " The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases." | 3.72 | New strategies for prevention of ischemic stroke: the LIFE study. ( Adams, HP, 2003) |
| " At similar blood pressure control, losartan, as compared to atenolol, reduced the relative risk of primary cardiovascular event (death, myocardial infarction, or stroke) by 13% (p = 0." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| "Atenolol was the beta-blocker most used." | 2.55 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Opie, LH; Volmink, J; Wiysonge, CS, 2017) |
| "Stroke has a high rate of recurrence; therefore secondary prevention is also important." | 2.50 | Beta-blockers for preventing stroke recurrence. ( Atallah, AN; da Silva, EM; De Lima, LG; Saconato, H, 2014) |
| "Stroke has a high rate of recurrence; therefore secondary prevention is also important." | 2.49 | Beta-blockers for preventing stroke recurrence. ( Atallah, AN; da Silva, EM; De Lima, LG; Saconato, H; Soares, BG, 2013) |
| "Initiating treatment of hypertension with beta-blockers leads to modest reductions in cardiovascular disease and no significant effects on mortality." | 2.48 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Mbewu, A; Opie, LH; Volmink, J; Wiysonge, CS, 2012) |
| "Mortality, pulmonary edema, and need for IABP were reduced by >50% (p < 0." | 1.32 | Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. ( Coleman, CI; Gallagher, R; Gillespie, EL; Horowitz, S; Kluger, J; Perkerson, KA; White, CM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 57 (64.04) | 29.6817 |
| 2010's | 30 (33.71) | 24.3611 |
| 2020's | 2 (2.25) | 2.80 |
| Authors | Studies |
|---|---|
| Redondo, M | 1 |
| Zarruk, JG | 1 |
| Ceballos, P | 1 |
| Pérez, DI | 1 |
| Pérez, C | 1 |
| Perez-Castillo, A | 1 |
| Moro, MA | 1 |
| Brea, J | 1 |
| Val, C | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 1 |
| Campillo, NE | 1 |
| Martínez, A | 1 |
| Gil, C | 1 |
| Feinberg, JB | 1 |
| Nielsen, EE | 1 |
| Kjeldsen, SE | 17 |
| Devereux, RB | 23 |
| Gerdts, E | 8 |
| Wachtell, K | 14 |
| Olsen, MH | 9 |
| Whiteley, WN | 1 |
| Gupta, AK | 1 |
| Godec, T | 1 |
| Rostamian, S | 1 |
| Whitehouse, A | 1 |
| Mackay, J | 1 |
| Sever, PS | 5 |
| Zhang, Y | 2 |
| Sun, N | 1 |
| Jiang, X | 1 |
| Xi, Y | 1 |
| Huang, L | 1 |
| Shang, E | 1 |
| Fan, W | 1 |
| Li, X | 1 |
| Li, B | 1 |
| He, S | 1 |
| Fu, Y | 1 |
| Li, Y | 1 |
| Fang, W | 1 |
| Choi, MH | 1 |
| Lee, JS | 1 |
| Lee, SE | 1 |
| Lee, SJ | 1 |
| Yoon, D | 1 |
| Park, RW | 1 |
| Hong, JM | 1 |
| Gaziano, TA | 1 |
| Pandya, A | 1 |
| Sy, S | 1 |
| Jardim, TV | 1 |
| Ogden, JM | 1 |
| Rodgers, A | 1 |
| Weinstein, MC | 1 |
| Mashour, GA | 1 |
| Sharifpour, M | 1 |
| Freundlich, RE | 1 |
| Tremper, KK | 1 |
| Shanks, A | 1 |
| Nallamothu, BK | 1 |
| Vlisides, PE | 1 |
| Weightman, A | 1 |
| Matlen, L | 1 |
| Merte, J | 1 |
| Kheterpal, S | 1 |
| De Lima, LG | 2 |
| Soares, BG | 1 |
| Saconato, H | 2 |
| Atallah, AN | 2 |
| da Silva, EM | 2 |
| Ashes, C | 2 |
| Judelman, S | 2 |
| Wijeysundera, DN | 1 |
| Tait, G | 2 |
| Mazer, CD | 2 |
| Hare, GM | 2 |
| Beattie, WS | 2 |
| Eisenach, JC | 1 |
| Bang, CN | 2 |
| Aurigemma, GP | 1 |
| Boman, K | 5 |
| de Simone, G | 2 |
| Dahlöf, B | 25 |
| Køber, L | 1 |
| Kuyper, LM | 1 |
| Khan, NA | 2 |
| Wicker, JF | 1 |
| Bronheim, D | 1 |
| Wijeysundera, D | 1 |
| DiNicolantonio, JJ | 1 |
| Fuchs, FD | 1 |
| O'Keefe, JH | 1 |
| Li, M | 1 |
| Jiang, D | 1 |
| Yu, S | 1 |
| Wang, Y | 2 |
| Kuyper, L | 1 |
| Vishram, JK | 1 |
| Ibsen, H | 13 |
| Lindholm, LH | 10 |
| Mancia, G | 5 |
| Okin, PM | 4 |
| Rothwell, PM | 3 |
| Roman, MJ | 1 |
| Palmieri, V | 1 |
| Nieminen, MS | 9 |
| Papademetriou, V | 2 |
| Hille, DA | 4 |
| Kamel, H | 1 |
| Mancusi, C | 1 |
| Midtbø, H | 1 |
| Lønnebakken, MT | 2 |
| Wiysonge, CS | 2 |
| Bradley, HA | 2 |
| Volmink, J | 2 |
| Mayosi, BM | 2 |
| Opie, LH | 2 |
| Füessl, HS | 1 |
| Bangalore, S | 2 |
| Messerli, FH | 7 |
| Cohen, JD | 2 |
| Bacher, PH | 1 |
| Sleight, P | 2 |
| Kowey, P | 1 |
| Zhou, Q | 2 |
| Champion, A | 4 |
| Pepine, CJ | 6 |
| Ostergren, J | 1 |
| Poulter, NR | 4 |
| Wedel, H | 9 |
| Beevers, G | 7 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kristinsson, A | 1 |
| McInnes, GT | 1 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 2 |
| Franklin, SS | 2 |
| Howard, SC | 2 |
| Dolan, E | 1 |
| Dobson, JE | 1 |
| Larstorp, AC | 1 |
| Saad, MA | 1 |
| Abbas, AM | 1 |
| Boshra, V | 1 |
| Elkhateeb, M | 1 |
| El Aal, IA | 1 |
| Carey, KM | 1 |
| Comee, MR | 1 |
| Donovan, JL | 1 |
| Kanaan, AO | 1 |
| Poirier, L | 1 |
| Lacourcière, Y | 1 |
| Mbewu, A | 1 |
| Böhm, S | 1 |
| Julius, S | 9 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| de Faire, U | 7 |
| Fyhrquist, F | 8 |
| Kristianson, K | 6 |
| Lederballe-Pedersen, O | 7 |
| Omvik, P | 8 |
| Oparil, S | 8 |
| Snapinn, S | 1 |
| Karpov, IuA | 1 |
| Adams, HP | 1 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 1 |
| Grossman, E | 1 |
| Fournier, A | 2 |
| Oprisiu, R | 1 |
| Andrejak, M | 1 |
| Fernandez, L | 1 |
| Achard, JM | 1 |
| Baumgart, P | 2 |
| Diener, HC | 2 |
| Stöllberger, C | 1 |
| Slany, J | 1 |
| Brainin, M | 1 |
| Finsterer, J | 1 |
| Burke, TA | 2 |
| Krobot, K | 1 |
| Carides, GW | 3 |
| Edelman, JM | 3 |
| Reims, HM | 3 |
| Brady, WE | 2 |
| Tuxen, C | 1 |
| Fossum, E | 2 |
| Bang, LE | 1 |
| Hall, C | 1 |
| Rokkedal, J | 1 |
| Hildebrandt, P | 1 |
| Borch-Johnsen, K | 1 |
| Mogensen, CE | 1 |
| Wan, Y | 2 |
| Coleman, CI | 1 |
| Perkerson, KA | 1 |
| Gillespie, EL | 1 |
| Kluger, J | 1 |
| Gallagher, R | 1 |
| Horowitz, S | 1 |
| White, CM | 1 |
| Ghali, JK | 1 |
| Kizer, JR | 2 |
| Snapinn, SM | 3 |
| Harris, KE | 2 |
| Lehto, M | 1 |
| Hornestam, B | 1 |
| Bourassa, MG | 1 |
| Lyle, PA | 4 |
| Jönsson, B | 2 |
| Dasbach, EJ | 1 |
| Safar, ME | 1 |
| O'Rourke, MF | 1 |
| Kowey, PR | 1 |
| Kupfer, S | 3 |
| Kolloch, RE | 1 |
| Benetos, A | 3 |
| Coca, A | 2 |
| Cooper-DeHoff, RM | 2 |
| Handberg, E | 1 |
| Gaxiola, E | 1 |
| Conti, CR | 2 |
| Hewkin, AC | 3 |
| Tavazzi, L | 1 |
| Høieggen, A | 2 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Singh, S | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Kolloch, R | 1 |
| Cooper-Dehoff, R | 1 |
| Bakris, GL | 1 |
| Erdine, S | 1 |
| Otterstad, JE | 1 |
| Oikarinen, L | 1 |
| Rahn, KH | 1 |
| Boersma, C | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Postma, MJ | 1 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Flaa, A | 1 |
| Os, I | 2 |
| Chattopadhyay, A | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Ling, G | 1 |
| Liu, AJ | 1 |
| Shen, FM | 1 |
| Cai, GJ | 1 |
| Liu, JG | 1 |
| Su, DF | 1 |
| Franco, V | 1 |
| Manhem, K | 1 |
| Perry, HM | 1 |
| Davis, BR | 1 |
| Price, TR | 1 |
| Applegate, WB | 2 |
| Fields, WS | 1 |
| Guralnik, JM | 1 |
| Kuller, L | 1 |
| Pressel, S | 1 |
| Stamler, J | 1 |
| Probstfield, JL | 1 |
| Franse, LV | 1 |
| Pahor, M | 1 |
| Di Bari, M | 1 |
| Shorr, RI | 1 |
| Wan, JY | 1 |
| Somes, GW | 1 |
| Gage, BF | 1 |
| Fihn, SD | 1 |
| White, RH | 1 |
| Einecke, D | 1 |
| Scheen, AJ | 1 |
| Montastruc, JL | 1 |
| Pathak, A | 1 |
| Lapeyre-Mestre, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for atenolol and Stroke
| Article | Year |
|---|---|
Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis.
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Atenolol; Coronary Disease; Human | 2017 |
Beta-blockers for preventing stroke recurrence.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Cause of Death; Humans; Ischemic Attack, Transient | 2013 |
Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Calcium Channel Blockers; Canada; Humans; | 2014 |
Beta-blockers for preventing stroke recurrence.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Humans; Ischemic Attack, Transient; Randomized Con | 2014 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2017 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydr | 2012 |
The evolving role of β-adrenergic receptor blockers in managing hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Cardiac Output; Cardiovascular Dise | 2012 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2012 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Warfarin therapy for an octogenarian who has atrial fibrillation.
Topics: Aged; Aged, 80 and over; Analgesics; Anticoagulants; Antihypertensive Agents; Atenolol; Atrial Fibri | 2001 |
30 trials available for atenolol and Stroke
| Article | Year |
|---|---|
Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study.
Topics: Atenolol; Atrial Fibrillation; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2023 |
Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cerebrovascular Circulation; Double-Bli | 2018 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Fem | 2017 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Press | 2010 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hyperten | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2005 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
48 other studies available for atenolol and Stroke
| Article | Year |
|---|---|
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease | 2012 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholest | 2021 |
S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
Topics: Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cla | 2017 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost | 2019 |
Perioperative metoprolol and risk of stroke after noncardiac surgery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Ateno | 2013 |
Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Cohort Studies; Female; Humans; | 2013 |
Patient safety: anesthesiology contributions and supplements to the American Society of Anesthesiologists' Annual Meeting.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2013 |
Does β selectivity really affect outcome?
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2014 |
In reply.
Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post | 2014 |
It takes the right medications to prevent a million heart attacks and strokes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Health Promoti | 2014 |
Comment on Kuyper et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Humans; Hypertension; Stroke | 2015 |
Reply to letter from Li et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Humans; Hypertension; Stroke | 2015 |
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Fe | 2016 |
[Resting heart rate as prognostic parameter--a slow rate indicates strength].
Topics: Adrenergic beta-Antagonists; Atenolol; Benzazepines; Coronary Disease; Cyclic Nucleotide-Gated Catio | 2008 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Dise | 2009 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor | 2010 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-R | 2002 |
[Preventing stroke. Which antihypertensive drugs can do it better?].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as T | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol | 2003 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; F | 2003 |
Regression dilution of systolic and diastolic blood pressure in patients with established cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atenolol; Blood Press | 2003 |
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Los | 2003 |
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; | 2004 |
Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Cardiac Surgical Procedures; Cohor | 2004 |
Cerebroprotection mediated by angiotensin II.
Topics: Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Humans; Research Design; Stroke | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Bli | 2005 |
Pulse pressure and antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Synergism; Drug Therapy | 2007 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pr | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Endpoint Determination; Humans; Losartan; Stroke; Treatment Outco | 2002 |